Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for May 2012
May 1, 2012
- Advaxis Research Accepted for American Association of Immunologists Annual Meeting, Demonstrates Reduction of Tumor Defenses
- Celldex Announces Plans to Release Topline Results from the EMERGE Study in Advanced Breast Cancer
- NanoViricides to Present at the 21st Annual NYBA Meeting in NYC on May 2nd
- Spectrum Pharmaceuticals to Present at the Deutsche Bank 37th Annual Health Care Conference
- Dyax Corp. to Participate in the Deutsche Bank 37th Annual Healthcare Conference
- Pharmacoeconomic Analysis Shows SURFAXIN May Reduce Hospital Cost Associated with Reintubation in Premature Infants
- ClinStar to Present at Outsourcing in Clinical Trials Europe
- Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
- New Study Demonstrates Dosing Non-Compliance Increases RSV-Related Hospitalizations Among High-Risk Babies In Medicaid Population
- Vulvodynia Study accepted into Journal of Lower Genital Tract Disease
- Epizyme to Participate in Upcoming Conferences in May
- Incyte to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
- Gilead Sciences to Present at the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8
- Idera Pharmaceuticals Announces Presentation of Preclinical Data of IMO-8400 in Both Lupus and Psoriasis Models
- Anacor Pharmaceuticals to Present at the Deutsche Bank Annual Health Care Conference
May 2, 2012
- Anti-HIV Drug Use During Pregnancy Does Not Affect Infant Size, Birth Weight
- Zalicus Advancing Z160, Its Novel, Oral N-type Calcium Channel Blocker, into Multiple Phase 2a Clinical Trials for the Treatment of Pain
- Recent Publicly-Funded CATT Trial Highlights Serious Safety Concerns Around Unlicensed Ocular Bevacizumab Use Versus Lucentis
- Advaxis Announces Abstracts Accepted for Poster Presentation at ASCO Annual Meeting 2012
- Global Pharmaceutical Leaders All Converging in Parsippany, New Jersey on September 11-12, 2012 for Breakthrough Event
- Imiquimod-induced psoriasis-like preclinical model for skin inflammation
- AVEO Announces Preliminary Results of Exploratory Phase 2 Study Evaluating HGF Inhibitor in First-Line Patients with Advanced Lung Cancer
- Mirna Therapeutics Publishes Preclinical Data Demonstrating Therapeutic Effects of microRNA in Hematological Cancer
- Azelon Pharmaceuticals Announces Completion of Phase 2 Trial Studying Nasal Spray Formulation of Teriparatide in Development for Osteoporosis
- RBCC Target Amarantus BioSciences Reports Positive Pre-Clinical Results of Parkinson's Treatment
- THE SAGE GROUP LLC Announces That Mary L. Yost, President, Will Lecture on Peripheral Artery Disease (PAD) Prevalence and Economics at the NEW CARDIOVASCULAR HORIZONS Conference
- Baxter to Present at Bank of America Merrill Lynch 2012 Healthcare Conference
- Abbott to Present at Deutsche Bank 37th Annual Health Care Conference
- Preventing autism after epilepsy
- Biogen Idec to Present at the Deutsche Bank 37th Annual Healthcare Conference
May 3, 2012
- Idera Pharmaceuticals Announces Top-line Results from a Phase 2 Clinical Trial of IMO-2055 in Treatment of Patients with Advanced Head and Neck Cancer
- VIVITROL Data to be Presented at Upcoming American Psychiatric Association Annual Meeting
- NovaBay's Aganocide Out-Performed Traditional Antibiotics in Drug Resistance Study
- Arrowhead to Present at Series of Upcoming Scientific Conferences
- Successful Outcome for V81444 in Phase I Study
- Midatech and MonoSol Rx Announce Positive Phase 1 Clinical Results for Their Novel Transbuccal Oral Insulin Film Product
- Genentech Reports Positive Study of Actemra Given by Subcutaneous Injection
- Examination of Registered Clinical Trials Suggests Weakness in Size and Methodology of Many Studies
- Lightlake Therapeutics Inc. Announces Positive Preliminary Phase II Clinical Trial Results of Binge Eating Disorder Treatment
- Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argos's Arcelis Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
- Biovest Announces that New Clinical Data for BiovaxID Personalized Cancer Vaccine will be Presented by National Cancer Institute at ASCO
- FibroGen Announces Promising Preliminary Data from an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals with Idiopathic Pulmonary Fibrosis (IPF) and Provides Program Update
- Dana-Farber's Belfer Institute for Applied Cancer Science to Present at AACR Special Conference Molecular Targeted Therapies: Mechanisms of Resistance
- Study Identifies Possible Protective Blood Factors Against Type 2 Diabetes
- Synta to Present at the Deutsche Bank 37th Annual Health Care Conference
- Former CMS Head Berwick, Harvard's Christensen keynote SAS Health Care and Life Sciences Executive Conference
- NPS Pharmaceuticals Reports Four Additional Patients Achieve Independence from Parenteral Support in STEPS 2 Study of Gattex in Adult Short Bowel Syndrome
- Amgen to Present at the Deutsche Bank 37th Annual Healthcare Conference
May 4, 2012
- Stallergenes Announces Positive Clinical Results for Its House Dust Mites Immunotherapy Tablet
- Teva to Present New Data on Women's Health Products at the American Congress of Obstetricians and Gynecologists Annual Clinical Meeting
- Genocea Highlights Key Progress in the Development of its First Vaccine Candidate, Targeting HSV-2
- Raptor Pharmaceutical Announces Publication of Phase 3 Results in the Clinical Journal of the American Society of Nephrology
- FibroGen Announces Promising Preliminary Data from an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals with Idiopathic Pulmonary Fibrosis (IPF) and Provides Program Update
- Pfizer Reports Top-Line Results From Phase 3 Trial Of Lyrica (pregabalin) Capsules CV In Patients With Inadequately Treated Painful Diabetic Peripheral Neuropathy
- Apricus Biosciences Announces Poster Presentation of Femprox Phase III Clinical Data at American Urological Association Annual Meeting
May 7, 2012
- Novartis Drug Pasireotide LAR Shows Superior Efficacy Compared to Sandostatin LAR in Phase III Trial of Patients With Acromegaly
- Interim Data from Phase 2 Combination Study of VX-809 and KALYDECO (ivacaftor) Showed Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
- Dainippon Sumitomo Pharma Reports that Latuda (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression
- CytRx Announces Presentation of Complete Clinical Data from INNO-206 Phase 1b/2 Trial at ASCO
- Galleon Pharmaceuticals Reports Positive Results from Phase I Study of GAL-021 For Treatment of Respiratory Depression
- Idera Pharmaceuticals Announces Efficacy Data for IMO-8400 in Preclinical Models of Lupus and Psoriasis
- Pfizer Announces New Long-Term Relapse Prevention Data For (desvenlafaxine) 50 mg/day For The Treatment Of Major Depressive Disorder In Adults
- PROLOR Biotech Announces Top-Line Results from Four-Month Treatment Extension of its Long-Acting Human Growth Hormone Phase II Trial
- Octagon Research Solutions, Inc. Named Emerging Life Sciences Company of the Year
- Promedior Announces Presentation of Preclinical Data at ARVO Demonstrating that Pentraxin-2 Suppressed Fibrosis, Neovascularization, and Vascular Leakage
- Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets
- Results from a Phase 3 Study of Once-Monthly Aripiprazole Intramuscular (IM) Depot Formulation for the Maintenance Treatment of Schizophrenia Presented at APA Annual Meeting
- NovaDigm Therapeutics Presents Positive Safety and Immunogenicity Data in a Second Phase 1 Study for NDV-3 Vaccine
- Clinverse Receives $3.8 Million to Expand Its Financial Technology for Clinical Trials
- Acucela Announces New Data from Its Phase 2a Trial of ACU-4429 in Patients with Advanced Dry AMD/Geographic Atrophy
- KYTHERA Biopharmaceuticals Announces Presentation of Positive Results from First of Two ATX-101 European Phase III Trials for Reduction of Submental Fat
May 8, 2012
- Eleven Biotherapeutics Presents Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease
- Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
- Erectile Dysfunction Drug May Benefit Cardiac Function in Young Patients with Heart Defects
May 9, 2012
- Merck PETACC-8 Study of Erbitux as Adjuvant Treatment in Colon Cancer Shows no Benefit at Pre-specified Interim Analysis
- Risk of Stroke Greater for Women Than Men Among Older Patients Diagnosed With Atrial Fibrillation, Regardless of Anticoagulant Use
- DARA BioSciences Announces New Analysis of Patient Self-Reported Diary Results in a Phase 2a Clinical Trial of KRN5500 in Patients With Cancer and Neuropathic Pain
- The International Myeloma Foundation Says Three Studies Highlighting Myeloma Treatment-Advances Are Featured Together in the Prestigous New England Journal of Medicine
- Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Peyronie's Phase IIb Study Published In The Journal Of Urology
- Newly-Published Study Compares SURFAXIN LS and CUROSURF in Well-Established Model of Respiratory Distress Syndrome
- Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
- Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo (zolpidem tartrate) Sublingual Tablets CIV
May 10, 2012
- New data among 200 Lucentis® abstracts at ARVO show low number of injections with Novartis drug required to achieve and maintain vision gains over 3 years in AMD and DME patients
- Andromeda Announces That Further Data Analyses Support Primary Endpoint in Andromeda Biotech's Phase III Clinical Study
- BELLUS Health announces update on the Phase III trial for KIACTA in AA amyloidosis presented at the XIII International Symposium on Amyloidosis
- New England Journal of Medicine Reports on Three Phase III Revlimid (Lenalidomide) Trials in Patients With Newly Diagnosed Multiple Myeloma
- New Data Among 200 Lucentis Abstracts at ARVO Show Low Number of Injections With Novartis Drug Required to Achieve and Maintain Vision Gains Over 3 Years in AMD and DME Patients
- Tekmira's LNP Technology Enables Alnylam's ALN-TTR01 Clinical Data
May 11, 2012
- Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely Active Crohn's Disease Met Primary Endpoints of Improvement in Clinical Remission in Induction and Maintenance Phases
- Cytochroma announces positive Phase 2b results for CTAP101 Capsules at National Kidney Foundation Meeting
- Ampio Pharmaceuticals Reports Pre-IND Meeting With the FDA to Obtain Clinical Path Guidance for Ampion(TM) for the Treatment of Chronic Pain of Osteoarthritis of the Knee and Schedules May 16th Webcast to Update Shareholders
- Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
May 14, 2012
- Ventrus Biosciences Announces Positive Results From Pivotal Phase 3 Trial of Diltiazem (VEN 307) in Patients With Anal Fissures
- MOLOGEN AG - Excellent outcome for phase 2 colorectal cancer study with MGN1703 - primary endpoint achieved
- HIV/AIDS Update - Tentative approval of nevirapine tablets 200 mg
- Study Reports Catheter Ablation Superior to Drug Therapy as First-Line Treatment for Atrial Fibrillation
- Results of Phase II Study of ONO-2745/CNS 7056, a Short-acting General Anesthetic
- FDA Drug Safety Communication: Revised Recommendations for Cardiovascular Monitoring and Use of Multiple Sclerosis Drug Gilenya (Fingolimod)
- Statistically Significant Clinical Phase III Results of Lu AA21004 Provide Basis for Submission of An NDA and MAA for Major Depression (MDD)
- SLA Pharma AG Announces Clinically and Statistically Significant Phase 2 Results on Opioid Induced Constipation
- New Allon research presented at leading scientific symposium
May 15, 2012
- Hydromorphone Hydrochloride Injection 1 MG/ML, (C-II) 1 ML Fill In 2.5 ML Carpuject: Recall - May Contain More Than the Intended Fill Volume
- ACH-3102 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C
- Theraclone Sciences Announces Positive Top-line Data from a Phase 1 Trial of its Therapeutic Antibody Directed at Influenza A
- Pulmatrix Demonstrates iSPERSE Capabilities for Inhaled Dry Powder Delivery of Antibiotics and Antibodies
- Elixir Medical Announces Continued Excellent One Year Safety and Efficacy Data from the EXCELLA BD Randomized Clinical Trial for DESyne BD Novolimus Eluting Coronary Stent with Biodegradable Polymer
- Boston Scientific Announces Positive Data From Lotus Transcatheter Aortic Valve Trial
- INTAC Technology Combats Misuse of Extended Release Drugs
- U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility for Production of ORENCIA (abatacept)
- Achaogen Announces All Objectives Met in Phase 2 Plazomicin Complicated Urinary Tract Infections Study and Start of First-in-Human Study with ACHN-975
- One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY Stent Versus PROMUS Element Platinum Chromium Stent
- AXIOS Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
- Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra(R) in Combination With Revlimid and a Genomic Study Designed to Identify Genes That Predict Response to Telintra in Patients With Myelodysplastic Syndrome
- Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda
- Alnylam Presents Final Results from a Phase I Clinical Trial of ALN-TTR01, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)
May 16, 2012
- Coping With New FDA Mandates For Drug Sample Distribution
- Bristol Myers Squibb Anticipates Significant Decline In Sales In The US For Clopidogrel
- Pfizer Provides Topline Results From Phase 3 Study Of Torisel As Second-Line Treatment In Advanced Renal Cell Carcinoma (RCC)
- Amneal Upgrades Generic Metformin Family by Listening to Customers
- Viropro, Inc. to Unlock Value from its Biosimilars Portfolio
- Arthritis Foundation Calls on Groups to Help Boost Physical Activity Among Adults with Arthritis
- Generic Plavix to Arrive at All Walmart and Sam's Club Pharmacies on May 19
- Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
- ImmunoGen, Inc. Announces Presentations at 2012 ASCO Annual Meeting on Product Candidates with the Company's TAP Technology
- STENTYS Self-Apposing Stent shows very low mortality at one month in 1,000 high-risk heart attack patients
- InVivo Therapeutics Chief Science Officer Edward Wirth to Discuss Biopolymers and Hydrogels for SCI at Rick Hansen's Interdependence 2012
- SOCMA's BPTF Welcomes House Committee Passage of FDA Reform Act
- Clinical Data Published for a Phase I AADC-deficiency Trial Using a Gene Therapy Manufactured by Florida Biologix
- Reminder: Exelixis Announces Data Presentations, Webcast of Investor Briefing in Conjunction With 2012 ASCO Annual Meeting
- MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
- Elevation Pharmaceuticals Announces Positive Phase 2b Results for EP-101 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
- Cannabis Science Receives New Photos and Information on Patient Three's Previous Examinations and the Current Progress on his Severe Squamous Cell Carcinoma
- Elixir Medical Announces Excellent Results from DESolve I First-In-Man Study for the Fully Bioresorbable Drug Eluting Coronary Scaffold System
- Inovio Pharmaceuticals' Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
- Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
- CVS Caremark Focus on Medication Adherence Saves PBM Clients Nearly $2.4 Billion in 2011
- Array BioPharma Announces Clinical Data Presentations at the 2012 ASCO Annual Meeting
May 17, 2012
- MorphoSys to Present MOR208 Preclinical Combination Therapy Data at ASCO Meeting
- NVA237 Phase III Data Showed Rapid, Sustained Improvement in Lung Function and Symptom Relief Over One Year in COPD Patients
- Novartis NVA237 Phase III data showed rapid, sustained improvement in lung function and symptom relief over one year in COPD patients
- Messaging in Anticoagulants Category ahead of Plavix Patent Loss
- FDA Receives Repros' Submission for Special Protocol Assessment Documentation for Pivotal Studies for Androxal
- Frost & Sullivan: New Innovations in the Rapidly Growing U.S. Breast Cancer Pharmaceutical Market
- New Competitive Arena Emerges for Pharmaceutical Companies in Healthcare's Changing Payment Landscape, Finds PwC Health Research Institute Study
- Children with Cancer Have Complete Responses in a Children's Oncology Group Phase 1 Trial
- Tokai Pharmaceuticals' Galeterone Phase 1 Data in Patients with Advanced Prostate Cancer to be Presented at ASCO Annual Meeting 2012
- AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
- Positive Phase 2 Clinical Data with Tivantinib in Hepatocellular Carcinoma to Be Highlighted in Oral Presentation at 2012 Annual Meeting of American Society of Clinical Oncology
- Puma Biotechnology to Present Clinical Data on PB272 at ASCO 2012 Annual Meeting
- Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent Compared to the TAXUS Stent Shown in Two Clinical Trial Subgroup Analyses
- UCSD Doctoral Pharmacy Students' Manuscripts Addressing Metabolism of Five Most Prescribed Pain Medications Published in Journal of Analytical Toxicology
- Idaho Technology Receives FDA 510(k) Clearance for Expanded FilmArray Respiratory Panel
- NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
- Phase 3 Data Show NUCYNTA ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
- Large-Scale Meta-Analysis Shows Age Not a Social Barrier to Opioid Use and Misuse
- Pharmaceutical Industry Labor-Management Association (PILMA) Statement on Prescription Drug User Fee Act (PDUFA)
- New Analysis of Risk Stratification for TYSABRI Published in New England Journal of Medicine
- Pharmos Corporation Announces Successful Completion Of Proof-of-concept Clinical Trial Of Levotofisopam For The Treatment Of Gout
- Neurocrine Biosciences Announces Urocortin 2 Phase II Study Results in Patients With Acute Decompensated Heart Failure
- Synta Announces Presentations at the 2012 American Society for Clinical Oncology (ASCO) Annual Meeting
- Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
- Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
- Ceregene Parkinson's Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
- New Data from Silence's Atu027 Anticancer Trial Published at ASCO
- Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
- Aptia Systems Presents at FDA's "Modernizing the Regulation of Clinical Trials and Approaches to Good Clinical Practices"
May 18, 2012
- Genetic Immunity Clinical Trial Data Published in PLoS ONE
- Santarus Announces Presentation of UCERIS Phase III Extended Use Data at Digestive Disease Week Meeting
- Bionest Publishes Landmark Article on Quantitative Financial Analysis of Personalized Medicine Strategies
- Dr. Reddy's Announces the Launch of Clopidogrel Tablets, USP
- Pfizer Exploratory Study Measures Effects Of Lyrica (pregabalin) On Brain Activity In Fibromyalgia Patients
- Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
- ZYTIGA (abiraterone acetate) Data to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting
- Purdue Pharma L.P. To Present Analysis Of Butrans (buprenorphine) Transdermal System CIII Clinical Data At American Pain Society Annual Meeting
- Actavis Launches First Generic Equivalent of Requip XL (Ropinirole Extended-Release Tablets)
- Forest and Almirall to Present Aclidinium Bromide Clinical Data at the American Thoracic Society (ATS) International Conference
- Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting
- Biovest Announces BiovaxID ASCO Abstract Available On-line; NCI to Present Cancer Vaccine Data from Mantle Cell Lymphoma Study
- Celldex Therapeutics to Host Call to Announce Topline Results from the EMERGE Study in Advanced Breast Cancer
- UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012
- FDA Approves Generic Versions of Blood Thinner Plavix
- Novo Nordisk Celebrates New INDYCAR Partnership Featuring Indy 500-Themed Billboard in Times Square
- Medgenics to Present at the 11th Annual ILSI BIOMED 2012
- Mylan Launches Generic Version of Plavix Tablets
- Watson Confirms Lo Loestrin Fe Patent Challenge
- Baron and Budd Warns Women About Side Effects of YAZ, Yasmin
- Cardio3 BioSciences Has Been Selected to Present C3BS-CQR-1 Trial Data in Late Breaking Clinical Trial Session at European Society of Cardiology 2012 Heart Failure Congress
May 21, 2012
- Achillion Announces Additional Proof-of-Concept Data With ACH-2684 for the Treatment of Hepatitis C
- Peregrine Announces Positive Top-Line Data From Randomized, Double-Blind Bavituximab Phase II Trial in Second-Line Non-Small Cell Lung Cancer
- Heparin-like compounds inhibit breast cancer metastasis to bone
- Digestive Disease Week Presentations Support Therapeutic Potential for Gattex (teduglutide) as Novel Treatment for Adult Short Bowel Syndrome
- BIOTRONIK Announces Positive Results for the Passeo-18 Lux Peripheral Vascular Paclitaxel Releasing Balloon
- Dendreon Announces Data Presentation at the 2012 American Urological Association Annual Meeting
- BIOTRONIK Announces Positive Results for Pantera Lux Paclitaxel Releasing Balloon in both Diabetic and Nondiabetic Subgroups
- VBL Therapeutics Presents Positive Preclinical Data for VB-201 in Inflammatory Bowel Disease at Digestive Disease Week (DDW) 2012
- Pulmatrix Announces Presentation of Clinical Data Demonstrating iCALM Inhaled Therapeutic Reduced Airway Inflammation
- New Phase 3 Study Results Show Anti-TNF SIMPONI Induced Clinical Response in Adults With Moderately to Severely Active Ulcerative Colitis
- Results of Phase II Study of Boehringer Ingelheim's Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
May 22, 2012
- ASH Annual Scientific Meeting Features Several Late-Breaking Presentations
- Celtic Pharma Announces Successful Completion of Phase I/II study of Xerecept in Pediatric Patients with Cerebral Tumors
- Tesetaxel Results as Initial Chemotherapy for Women With Recurrent Breast Cancer to be Highlighted at ASCO
- Catalyst Pharmaceutical Partners Reports Positive Results From Phase I(a) Clinical Study of CPP-115
- Phase 3 MISSION Trial of Nexavar (Sorafenib) in Patients With Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
- Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
- Pharmacokinetics Parameters of Sunshine Biopharma's Lead Anti-Cancer Compound Exceed Expectations
- Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
- Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
- Treatment with Bisphosphonates Associated With Increased Risk of Atypical Femoral Fractures
- Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
- Data From NewLink Genetics Phase 2 Trial of Its HyperAcute Pancreas (Algenpantucel-L) Immunotherapy to be Presented at the 2012 Digestive Disease Week
- Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
- Results of Phase II Study of Boehringer Ingelheim?s Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
- Apricus Biosciences Granted Regulatory Meeting With FDA for Femprox for the Treatment of Female Sexual Arousal Disorder
May 23, 2012
- Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO data Presented at the European Atherosclerosis Society 2012 Meeting
- U.S. Marshals Seize Unapproved New Drug From Crescendo Therapeutics LLC
- FDA-Led Research Team Discovers An Autoimmune Mechanism for Serious Drug-Induced Adverse Reactions
- Phase 3 Study Shows Efficacy Is Maintained With Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents With ADHD After at Least 6 Months of Treatment
- Millennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Meeting
- Common Acne Medication Doubles Risk of Eye Infections
- BioTime and Subsidiary LifeMap Sciences, Inc. Announce Agreement to Market MalaCards - A Database of Human Diseases
- Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
- Musculoskeletal Network Reports from American Pain Society Meeting
- Alvine Pharmaceuticals Presents Results from a Phase 2A Trial of ALV003 in Celiac Disease Patients at the 2012 Digestive Diseases Week Meeting
- Celldex's CDX-011 Demonstrates High Response Rates in Patients with Metastatic Breast Cancer Expressing Elevated Levels of GPNMB and in Triple Negative Disease
- Immune cells "sculpt" circuits in the brain -- by eating away excess connections
- Senesco's SNS01 is a Potent Regulator of Programmed Cell Death and Tumor Growth in Murine Models of Multiple Myeloma
May 24, 2012
- Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
- Celldex?s Cdx-011 Demonstrates High Response Rates in Patients With Metastatic Breast Cancer Expressing Elevated Levels of Gpnmb and in Triple Negative Disease
- MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma Exacerbations
- Kancera´s ROR inhibitors are active against Fludarabine resistant leukemia
- Hospira Carpuject Pre-filled Cartridges - Drug Alert: Products May Contain More Than the Intended Fill Volume
- New Phase 3 Data for Tradjenta (Linagliptin) Tablets in Black Or African American Patients With Type 2 Diabetes Showed Significant Improvement in Blood Sugar
May 25, 2012
- Apofore Founder Publishes Studies Identifying Apolipoprotein A-IV as New Potential Target for Type 2 Diabetes Therapeutics
- Heart disease and stroke deaths drop significantly for people with diabetes
May 29, 2012
- Update re: Late Pre-clinical Study of VAL201
- Acacia Pharma Announces Excellent Phase II Results for Apd421 in Post-Operative Nausea & Vomiting
- ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule Inhibitor of C5aR, at the 49th European Renal Association - European Dialysis and Transplant Association Congress
- Andromeda Announces FDA Orphan Drug Designation for DiaPep277 for the Treatment of Type 1 Diabetes With Residual Beta Cell Function
- Tranzyme Pharma and Norgine Announce Top-Line Data From ULISES 008, the Second of Two Phase 3 Pivotal Trials Evaluating Ulimorelin
- Lundbeck's Lu AE58054 Meets Primary Endpoint in Large Placebo-Controlled Clinical Proof of Concept Study in People With Alzheimer's Disease
- Vertex Corrects and Provides Additional Data From Recent Interim Analysis of Phase 2 Combination Study of VX-809 and Kalydeco (Ivacaftor) in People With Cystic Fibrosis Who Have Two Copies of the F508del Mutation
- Researchers Restore Neuron Function to Brains Damaged by Huntington's Disease
- Winning The Battle Against Breast Cancer Metastasis
May 30, 2012
- Asian Cancer Research Group and BGI Report Findings from Genomics Research on Recurrent Hepatitis B Virus Integration, A Major Cause of Liver Cancer
- SCRI Investigators are Authors on 60 Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Alnylam Announces Top-Line Results of Phase IIb Clinical Trial of ALN-RSV01, an Inhaled RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection
- Biocept to Present Clinical Findings on Circulating Tumor Cells (CTCs) at the American Society for Clinical Oncology Annual Meeting
- FDA Warns Consumers about Counterfeit Version of Teva?s Adderall
- AVEO Oncology to Host Conference Call and Webcast to Review Phase 3 TIVO-1 Data Presented at ASCO
- Repros Updates Status of Proellex Clinical Programs
- Flexion's Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
- Oncology Experts from Cardinal Health Specialty Solutions Share Cancer Care Research at 2012 American Society of Clinical Oncology Annual Meeting
- One size doesn't fit all when treating blood pressure in people with diabetes, VA/U-M study suggests
- Senesco's SNS01-T to be Presented During Poster Session at 2012 Annual Meeting of the American Society of Clinical Oncology
- Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anti-Cancer Compound RX-3117
- Cell Therapeutics' Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
- Alkermes Presents Positive Clinical Data of ALKS 5461 at 52nd Annual New Clinical Drug Evaluation Unit Meeting
- Alkermes Announces Results from Phase 2 Study of ALKS 37 for Treatment of Opioid-Induced Constipation
May 31, 2012
- Novartis showcases ongoing research at ASCO to help patients fight various cancers, including updated data in advanced breast cancer
- Chelsea Therapeutics Reports Top-Line Results of Phase II Trial of CH-4051 in Rheumatoid Arthritis
- A.P. Pharma Announces Study Finding Continuous Exposure to a 5-HT3 Antagonist Using APF530 Provides Better Emetic Control
- Veloxis Pharmaceuticals to Present Results from a Patient Subgroup Analysis of Once-Daily LCP-Tacro(TM) in Stable African-American Kidney Transplant Patients at American Transplant Congress (ATC)
- The Multiple Myeloma Research Consortium (MMRC) Announces Oral and Poster Presentations at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting
